Relationship between enrichment of drug co-discussion in Medline and co-prescription from NHANES 2007–2008 and 2009–2010 surveys.

<p>Enrichment quantifies the extent to which a pair of drugs are co-discussed or co-prescribed more (enrichment >1) or less (enrichment <1) than expected if discussed/prescribed independently. A) co-prescription enrichment for 4032 drug pairs, arising from 133 drugs prescribed in ≥0.1% of the population for both surveys (and based on 5 or more actual subjects in each of the last two surveys) vs. co-discussion enrichment in the literature; values shown on log scale and enrichment of 0 in literature (i.e. no Medline records describing both drugs together) is arbitrary shown at 0.001 on the Y-axis. The listed drug pairs exemplify low/high co-prescription and co-discussion. Drug pairs co-prescribed >3x more than expected are exemplified in green and red; in addition to above criteria, these drug pairs are co-prescribed in 0.3 percent or more of the population based on 5 or more actual subjects reporting the use of both drugs in each of the last two surveys. Drug pairs co-prescribed >3x less than expected are exemplified in blue and orange; these drugs have individual prescription rates ≥1% in the last two surveys. B) Probability of co-discussion enrichment >2 when co-prescription enrichment is analyzed in ranges.